α- and β-secretase:: profound changes in Alzheimer's disease

被引:153
|
作者
Tyler, SJ
Dawbarn, D
Wilcock, GK
Allen, SJ [1 ]
机构
[1] Univ Bristol, Bristol Royal Infirm, Mol Neurobiol Unit, URCN Care Elderly, Bristol BS2 8HW, Avon, England
[2] Frenchay Hosp, Dept Care Elderly, Bristol BS16 1LE, Avon, England
关键词
Alzheimer's disease; alpha-secretase; amyloid; apolipoprotein E; beta-secretase; BACE; choline acetyltransferase; TACE;
D O I
10.1016/S0006-291X(02)02635-9
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The amyloid plaque, a neuropathological hallmark of Alzheimer's disease, is produced by the deposition of beta-amyloid (Abeta) peptide, which is cleaved from Amyloid Precursor Protein (APP) by the enzyme beta-secretase. Only small amounts of Abeta form in normal brain; more typically this is precluded by the processing of APP by alpha-secretase. Here, we describe a decrease in alpha-secretase (81% of normal) and a large increase in beta-secretase activity (185%) in sporadic Alzheimer's disease temporal cortex. Since alpha-secretase is present principally in neurons known to be vulnerable in Alzheimer's disease, and there is known competition between alpha- and beta-secretase for the substrate APP, it is significant that the majority of Alzheimer samples tested here were low in a-secretase. Eighty percent of Alzheimer brains examined had an increase in beta-secretase, a decrease in alpha-secretase, or both; which may account for the means by which the majority of people develop Alzheimer's disease. (C) 2002 Elsevier Science (USA). All rights reserved.
引用
收藏
页码:373 / 376
页数:4
相关论文
共 50 条
  • [41] Activation of α-secretase as an approach for treatment of Alzheimer's disease
    Fahrenholz, Falk
    Alzheimer: 100 Years and Beyond, 2006, : 255 - 259
  • [42] The β-Secretase BACE1 in Alzheimer's Disease
    Hampel, Harald
    Vassar, Robert
    De Strooper, Bart
    Hardy, John
    Willem, Michael
    Singh, Neeraj
    Zhou, John
    Yan, Riqiang
    Vanmechelen, Eugeen
    De Vos, Ann
    Nistico, Robert
    Corbo, Massimo
    Imbimbo, Bruno Pietro
    Streffer, Johannes
    Voytyuk, Iryna
    Timmers, Maarten
    Monfared, Amir Abbas Tahami
    Irizarry, Michael
    Albala, Bruce
    Koyama, Akihiko
    Watanabe, Naoto
    Kimura, Teiji
    Yarenis, Lisa
    Lista, Simone
    Kramer, Lynn
    Vergallo, Andrea
    BIOLOGICAL PSYCHIATRY, 2021, 89 (08) : 745 - 756
  • [43] γ-secretase as a therapeutic target for treatment of Alzheimer's disease
    Tomita, T
    Iwatsubo, T
    CURRENT PHARMACEUTICAL DESIGN, 2006, 12 (06) : 661 - 670
  • [44] Alzheimer's Beta-Secretase in Health and Disease
    Farah, Mohamed
    Wong, Philip C.
    FASEB JOURNAL, 2008, 22
  • [45] SEMAGACESTAT γ-Secretase Inhibitor Treatment of Alzheimer's Disease
    Davies, S.
    Pandian, R.
    Bolos, J.
    Castaner, R.
    DRUGS OF THE FUTURE, 2009, 34 (08) : 613 - 617
  • [46] Turning the tide on Alzheimer’s disease: modulation of γ-secretase
    Joanna E. Luo
    Yue-Ming Li
    Cell & Bioscience, 12
  • [47] Delta Secretase and BDNF Signalling in Alzheimer's Disease
    Unlu, Buse
    Ildiz, Sumeyra
    Ak, Duygu Gezen
    Dursun, Erdinc
    EXPERIMED, 2023, 13 (01): : 1 - 7
  • [48] γ-Secretase as a target for drug intervention in Alzheimer's disease
    Harrison, T
    Churcher, I
    Beher, D
    CURRENT OPINION IN DRUG DISCOVERY & DEVELOPMENT, 2004, 7 (05) : 709 - 719
  • [49] γ-secretase:: Structure, function, and modulation for Alzheimer's disease
    Wolfe, Michael S.
    CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2008, 8 (01) : 2 - 8
  • [50] Development and Mechanism of γ-Secretase Modulators for Alzheimer's Disease
    Crump, Christina J.
    Johnson, Douglas S.
    Li, Yue-Ming
    BIOCHEMISTRY, 2013, 52 (19) : 3197 - 3216